Brentuximab vedotin plus AVD for Hodgkin lymphoma: incidence and management of peripheral neuropathy in a multisite cohort

Brentuximab vedotin (BV) in combination with doxorubicin, vinblastine, and dacarbazine (AVD) is increasingly used for frontline treatment of stage III/IV classical Hodgkin lymphoma (cHL). Peripheral neuropathy (PN) was the most common and treatment-limiting side effect seen in clinical trials but ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Bowers, Jackson T., Anna, Jacob, Bair, Steven M., Annunzio, Kaitlin, Epperla, Narendranath, Pullukkara, Jerrin Joy, Gaballa, Sameh, Spinner, Michael A., Li, Shuning, Messmer, Marcus R., Nguyen, Joseph, Ayers, Emily C., Wagner, Charlotte B., Hu, Boyu, Di, Mengyang, Huntington, Scott F., Furqan, Fateeha, Shah, Nirav N., Chen, Christina, Ballard, Hatcher J., Hughes, Mitchell E., Chong, Elise A., Nasta, Sunita D., Barta, Stefan K., Landsburg, Daniel J., Svoboda, Jakub
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The American Society of Hematology 2023
Materias:
Lymphoid Neoplasia
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628810/
https://www.ncbi.nlm.nih.gov/pubmed/37595053
http://dx.doi.org/10.1182/bloodadvances.2023010622

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10628810/
https://www.ncbi.nlm.nih.gov/pubmed/37595053
http://dx.doi.org/10.1182/bloodadvances.2023010622

Ejemplares similares